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Abstract
In a typing system based on opsonic antibodies against carbohydrate antigens of the cell envelope, 60% of Enterococcus
faecalis strains can be assigned to one of four serotypes (CPS-A to CPS-D). The structural basis for enterococcal serotypes,
however, is still incompletely understood. Here we demonstrate that antibodies raised against lipoteichoic acid (LTA) from a
CPS-A strain are opsonic to both CPS-A and CPS-B strains. LTA-specific antibodies also bind to LTA of CPS-C and CPS-D
strains, but fail to opsonize them. From CPS-C and CPS-D strains resistant to opsonization by anti-LTA, we purified a novel
diheteroglycan with a repeating unit of R6)-b-Galf-(1R3)- b-D-Glcp-(1R with O-acetylation in position 5 and lactic acid
substitution at position 3 of the Galf residue. The purified diheteroglycan, but not LTA absorbed opsonic antibodies from
whole cell antiserum against E. faecalis type 2 (a CPS-C strain) and type 5 (CPS-D). Rabbit antiserum raised against purified
diheteroglycan opsonized CPS-C and CPS-D strains and passive protection with diheteroglycan-specific antiserum reduced
bacterial counts by 1.4 – 3.4 logs in mice infected with E. faecalis strains of the CPS-C and CPS-D serotype. Diheteroglycan-
specific opsonic antibodies were absorbed by whole bacterial cells of E. faecalis FA2-2 (CPS-C) but not by its isogenic
acapsular cpsI-mutant and on native PAGE purified diheteroglycan co-migrated with the gene product of the cps-locus,
suggesting that it is synthesized by this locus. In summary, two polysaccharide antigens, LTA and a novel diheteroglycan,
are targets of opsonic antibodies against typeable E. faecalis strains. These cell-wall associated polymers are promising
candidates for active and passive vaccination and add to our armamentarium to fight this important nosocomial pathogen.
Citation: Theilacker C, Kaczyn ´ski Z, Kropec A, Sava I, Ye L, et al. (2011) Serodiversity of Opsonic Antibodies against Enterococcus faecalis —Glycans of the Cell Wall
Revisited. PLoS ONE 6(3): e17839. doi:10.1371/journal.pone.0017839
Editor: Shan Lu, University of Massachusetts Medical Center, United States of America
Received October 14, 2010; Accepted February 15, 2011; Published March 18, 2011
Copyright:  2011 Theilacker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: ZK was supported by Polish Ministry of Research and Higher Education under grant no. N N301 030134. No other current external funding sources
supported this this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: johannes.huebner@uniklinik-freiburg.de
Introduction
The classification system for streptococci was developed by
Rebecca Lancefield at the beginning of the 20th century [1].
Enterococci were assigned to the serogroup D in the Lancefield
typing system, and the group-specific antigen was subsequently
identified as lipoteichoic acid (LTA) by Wicken and colleagues [2].
About fifty years later, our group demonstrated that antibodies
that opsonize E. faecalis strain 12030 bind to the group antigen
LTA [3]. In a recent serotyping system based on carbohydrate-
specific antibodies, 60% of E. faecalis strains were typeable and
assigned to four serotypes, designated CPS-A to CPS-D [4].
However, the structural equivalents of the type-specific antigens in
this serotyping system are still unknown. This is surprising because
several major carbohydrate structures of the enterococcal cell wall
were described by Pazur, Bleiweis, and Krause in a number of
landmark studies almost forty years ago [5,6,7,8]. These authors
identified two major glycans from cell wall extracts of E. faecalis:a
rhamnopolysaccharide (also called tetraheteroglycan or cell wall
polysaccharide) and a diheteroglycan. The rhamnopolysaccharide
was first described by Elliott et al. as the type antigen of Streptococcus
faecalis in 1960 [9]. Bleiweis and Krause characterized the type
antigen in more detail and reported that it is a complex
carbohydrate containing rhamnose, glucose, glucosamine, and
galactosamine as well as ribitol and phosphorus [8]. Rhamnopo-
lysaccharides of similar composition were also described by Pazur
and Karakawa [6] and in two more recent studies [10,11]. In the
early 1970ies, Pazur et al also isolated a polysaccharide containing
glucose and galactose from E. faecalis and named it diheterglycan
[5,6]. A number of more recent studies have investigated genetic
loci involved in the biosynthesis of polysaccharides of the
enterococcal cell envelope, but chemical structures of the
respective polysaccharides and their potential as vaccine antigens
have not been explored [11,12,13,14,15,16,17,18].
Enterococcus is currently ranked third among Gram-positive
pathogens to cause hospital-associated infections in the US [19]
and was the second most common pathogen isolated from ICU
patients worldwide in a point-prevalence study conducted in 2007,
causing 10% of nosocomial infections on the ICU [20]. With
limited options in antimicrobial chemotherapy available, a
renewed interest in alternative treatment and prevention strategies
such as active and passive immunization has evolved. Capsular
polysaccharides have been highly successful vaccine antigens for
vaccines against various bacterial pathogens, but little is known
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antibodies against E. faecalis. Hancock, Gilmore and Thurlow
[12,13,14,15] described a capsule in E. faecalis synthesized by the
cps locus. This capsule mediates resistance to killing by serum and
neutrophils or macrophages, augments bacterial persistence in
vivo, and impedes C3b deposition on the bacterial surface [4,14].
However, to date, no definite chemical structure of the capsular
polysaccharide has been published.
In the current study, we have revisited the cell wall
carbohydrates of E. faecalis and investigated their role as antigens
in the CPS-serotyping system by Hufnagel and colleagues. Using
highly purified polysaccharides, we were able to show that opsonic
antibodies are directed against only two of these antigens: In
acapsular strains, LTA is the major opsonic epitope and in
encapsulated strains opsonic antibodies bind to a novel diheter-
oglycan, the putative capsular polysaccharide of E. faecalis in CPS-
C and CPS-D strains.
Results
CPS-A and CPS-B strains but not CPS-C and CPS-D strains
are opsonized by LTA-specific antibodies
We reported previously that E. faecalis strains belonging to the
CPS-A serotype are opsonized by antibodies specific to a teichoic-
acid like polysaccharide, which was later shown to be structurally
identical to LTA [3,4]. More than half of the E. faecalis strains,
however, belong to serotypes CPS B – D and are not opsonized
by this antiserum [4,21]. To further explore the role of antibodies
against LTA in the serodiversity of E. faecalis strains, we
vaccinated a rabbit with LTA from E. faecalis 12030 (CPS-A),
which was extracted and purified using non-degrading condi-
tions. In a western blot analysis with whole cell lysates of the
vaccine strain this antiserum was monospecific to LTA (data not
shown). In the opsonophagocytic killing assay, anti-LTA
antibodies mediated killing not only of CPS-A strains, but also
of E. faecalis strains that belong to the CPS-B serotype. In
contrast, CPS-C and CPS-D strains were not opsonized (Fig. 1B).
Next, we wanted to explore if CPS-C and CPS-D strains may
express a structurally distinct LTA molecule that is not
recognized by antibodies that are raised against LTA from a
CPS-A strain. We purified LTA from three E. faecalis strains that
belonged to the serotypes CPS-B – CPS-D and measured binding
by ELISA (Fig. 1A). Anti-LTA bound equally well, however, to
LTA derived from CPS-A (E. faecalis 12030), CPS-B (12107),
CPS-C (FA2-2) and CPS-D (type 5) strains, suggesting that
antigenic variability of LTA is irrelevant for the lack opsonic
activity of LTA antiserum against CPS-C and CPS-D strains
(Fig. 1, for specifications of E. faecalis strains see table 1).
Purification of a novel capsular polysaccharide in CPS-C
and CPS-D strains
Since CPS-C and CPD-D strains are not killed by anti-LTA
antibodies, we hypothesized that LTA in these strains is masked by
a polysaccharide capsule, an assumption also supported by
agglutination experiments by Thurlow and coworkers [15]. To
investigate this hypothesis, we released cell wall associated
carbohydrates in CPS-C (E. faecalis FA2-2 and E. faecalis type 2)
and CPS-D (E. faecalis type 5) strains by enzymatic digestion of
peptidoglycan and separated the extracted material by gel-
permeation chromatography. Carbohydrate eluting at void
volume consisted of LTA as determined by
1H NMR analysis. A
large second peak eluting around a Kav of 0.45 was further
purified by anion-exchange chromatography. The majority of the
material eluted from Q-Sepharose around 300 mM NaCl and
contained rhamnose, glucose, galactose, N-acetylglucosamine and
N-acetylgalactosamine, as determined by sugar analysis. The
compositional analysis of this polysaccharide was consistent with
the previously described rhamnopolysaccharide [10,11,12,16,22].
A smaller, adjacent peak eluted at 450 mM NaCl and contained
only glucose and galactose. This material migrated as a single,
broad band around 100 kDa on SDS-PAGE electrophoresis and
stained positive with periodic acid-Schiff (PAS) but not with
Commassie blue (Fig. S1). Preliminary analysis by
1H-NMR
spectroscopy revealed that this material contained a novel
diheteroglycan and impurities of lipoteichoic acid, which were
removed by a final purification step using gel-permeation
chromatography on a Toyopearl column HW-40S. This final
preparation contained ,3% protein and ,1% phosphorus and
was used for consecutive chemical and biological analysis.
Structural analysis of capsular polysaccharide from
E. faecalis CPS-C and CPS-D strains reveals a novel
diheteroglycan
Compositional analysis identified the presence of D-Glc. The
1H NMR spectrum of the diheteroglycan isolated from E. faecalis
type 2 (CPS-C, Fig. 2A) showed two anomeric signals at d 5.297
(residue A, {
3JH1,H2 ,2H z } ) ,a n da td 4.491 (residue B, {
3JH1,H2 =
7.8 Hz}), which were assigned to H-1 of b-Galf and b-Glcp,
respectively. In addition, a broad signal at d 5.379 was identified,
which was assignedtoprotonH-5 of b-Galf due tothesubstitution of
position C-5 by an O-acetyl group (d 2.164). Furthermore, the
doublet at d 1.366 was recognized as methyl group belonging to
lactic acid (LA) residue [23,24,25].
All
1H and
13C chemical shifts of the capsular polysaccharides
were established from
1H,
1H correlation and total correlation as
well as
1H,
13C heteronuclear multiple quantum coherence NMR
experiments. Low-field shifted signals of carbon atoms demon-
strated substitutions at C-6 and C-3 of b-Galf (d 69.63 and d
84.85, respectively) and substitution at C-3 of b-Glcp (d 82.58) The
chemical shifts are summarized in table S1.
The sequence of the residues in the repeating unit of the
capsular polysaccharides was established by rotating frame nuclear
Overhauser effect (NOE) spectroscopy (ROESY, Fig. 2B) and
heteronuclear multiple bond correlation (HMBC, Fig. S2)
experiments. Strong interresidual NOE contacts were observed
between H-1 A/H-3 B (d 5.297/3.622), as well as between H-1
B/H-6a A (d 4.491/3.897), and H-1 B/H-6b A (d 4.491/4.101).
Additional weak NOE contacts were found between H-5 A and
LA methyl group (d 5.379/1.336), and H-5 A and O-acetyl methyl
group (d 5.379/2.164). The HMBC data confirmed the sequence
of the constituents assigned from ROESY data. The following
interresidual proton-carbon correlations were observed: H-1 A/C-3
B (d 5.297/82.58), C-1 A/H-3 B (d 109.20/3.622), C-1 B/H-6a A
(d 103.44/3.897), as well as H-3 A/C-2 LA (d 3.747/77.88), and
C-3 A/H-2 LA (d 84.85/3.966). The chemical structure of the
isolated polysaccharide is shown on the Fig. 2C.
1H NMR spectroscopy of diheteroglycans isolated from E.
faecalis FA2-2 (CPS-C) and type 5 (CPS-D) revealed a
polysaccharide that they only differed from the E. faecalis type
2 (CPS-C) diheteroglycan by their lack of O-acetylation of b-Galf
(for structural analysis of diheteroglycan from type 5 see Fig. S3,
S4 and table S2). In subsequent experiments we isolated O-
acetylated and O-deacetylated diheteroglycan from E. faecalis
type 2 using the same culture conditions. Thus, it cannot be
excluded that the chosen purification scheme may result in the
loss of the labile O-acetyl group during the isolation of the
polysaccharide.
Opsonic Antibodies against E. faecalis
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We previously generated antisera by vaccination with heat-
killed, proteinase K digested bacterial cells of E. faecalis type 2
(CPS-C) and type 5 (CPS-D) that opsonize CPS-C or CPS-D
strains [4]. The antisera contained antibodies that bound to LTA
but also antibodies that recognized enterococcal diheteroglycan
(Fig. 3A). Using both antigens as inhibitors in the opsonophago-
cytic killing assay, we assessed the specificity of opsonic antibodies
of the antisera against E. faecalis type 2 and type 5 (Fig. 3B). In
agreement with results obtained with antiserum against LTA
showing no opsonic activity against type 2 and type 5 strains,
purified LTA was also a poor inhibitor (i.e. ,10% inhibition) of
opsonophagocytic killing mediated by the serotype-specific
antiserum. Purified diheteroglycan, on the other hand, inhibited
98% of opsonic activity of antiserum against E. faecalis type 2
(CPS-C) and 88% of opsonic killing of E. faecalis type 5 (CPS-D) by
the respective antiserum indicating that the majority of opsonic
antibodies raised by whole cell vaccination are directed against this
antigen. To further explore the potential of diheteroglycan as
candidate for an enterococcal vaccine, we immunized a rabbit
with purified antigen from E. faecalis type 2 (CPS-C). Western blot
analysis of this antiserum with whole cells lysates of the same strain
as antigen confirmed the presence of antibodies against the high
molecular weight band of diheteroglycan. In addition, we detected
antibodies against a second, broad band that migrated around 20–
30 kDa, suggestive of antibodies against LTA (data not shown).
Diheteroglycan – like many other bacterial polysaccharide
antigens – was overall poorly immunogenic and induced only
moderate levels of specific antibodies as quantified by ELISA (Fig.
S5). We further investigated cross-reactivity of diheteroglycan-
specific antibodies by the opsonophagocytic killing assay (Fig. 4).
Figure 1. Cross-reactivity of antibodies directed against enterococcal LTA. (A) Binding of rabbit IgG raised against LTA purified from E.
faecalis strain 12030 to LTA extracted from E. faecalis strains of various CPS-serotypes. The coating antigens and serum dilutions are specified in the
legend. Each point represents the average of two determinations. (B) Opsonophagocytic killing of various E. faecalis strains by the same anti-LTA
rabbit antiserum. A serum dilution of 1:800 was used to assess killing activity. The respective target strains are indicated in the legend.
Opsonophagocytic killing activity was compared to controls from which leukocytes were omitted. Each bar represents the mean of four
determinations and the error bar the SEM.
doi:10.1371/journal.pone.0017839.g001
Table 1. E. faecalis strains used in the study.
Strain Serotype Source MLST* Synonym Reference
E. faecalis 12030 CPS-A clinical 64 [22]
E. faecalis 12107 CPS-B clinical 21 [22]
E. faecalis OG1RF CPS-B oral 1 [45]
E. faecalis type 1 CPS-B unknown 21 MCTC 8727 [26]
E. faecalis type 2 CPS-C urine 11 MCTC 8796 [26]
E. faecalis type 21 CPS-C infant/fecal 30 MCTC 8746 [26]
E. faecalis R19.001 CPS-C fecal unknown [46]
E. faecalis V583 CPS-C blood 6 ATCC700802 [47]
E. faecalis FA2-2 CPS-C clinical 8 [48]
E. faecalis HG101 – cpsI mutant of FA2-2 – [12]
E. faecalis type 5 CPS-D urine 68 MCTC 8731 [26]
*for reference, see [21].
doi:10.1371/journal.pone.0017839.t001
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were opsonic to all E. faecalis strains of the CPS-C and CPS-D
serotype evaluated (i.e. killing .70%). At higher serum dilutions,
opsonic killing activity of $50% was observed only for three out of
five heterologous E faecalis strains, indicating overall moderate
titers of opsonic antibodies induced by vaccination with diheter-
oglycan (Fig. 4).
Diheteroglycan shares antigenic and structural
similarities with the gene product of the cps locus
Hancock and Gilmore previously described a gene locus
involved in the biosynthesis of a putative capsular polysaccharide
of E. faecalis strains of the CPS-C and CPS-D serotype [12,14,15].
The product of the cps-locus is a capsular polysaccharide
composed of glucose, galactose, glycerol, and phosphate
[12,15]. To examine antigenic similarity of diheteroglycan and
the capsular polysaccharide produced by the cps locus, we
absorbed the antiserum raised against diheterglycan derived from
E. faecalis type 2 (CPS-C) with an acapsular cpsI mutant in E.
faecalis FA2-2 and the isogenic wild type strain (CPS-C) [12].
Absorption of diheteroglycan-specific rabbit antiserum with the
wild-type E. faecalis but not with the acapsular mutant abolished
opsonic killing of the E. faecalis FA2-2 (Fig. 5A). For comparison
of the biosynthetic product of the cps-locus with diheteroglycan
we released cell wall carbohydrates from E. faecalis FA2-2 and its
isogenic cpsI mutant and applied it along with purified
polysaccharide to acrylamide gel electrophoresis (Fig. 5B).
Electrophoretic mobility of diheteroglycan was identical to a
high molecular weight band around 100 kDa that was present in
E. faecalis FA2-2 wild type strain but not in the cpsI mutant
(Fig. 5B).
Antibodies to diheteroglycan protect against bacteremia
in mice
Having demonstrated that diheteroglycan-specific antibodies
are opsonic to E. faecalis CPS-C and CPS-D strains, we assessed
in vivo protection by passive immunization in a mouse
bacteremia model. To this end, BALB-C mice received rabbit
antibodies against diheteroglycan or against LTA (as a control)
48 h and 24 h before and 4 h after i.v. challenge. A total of three
E. faecalis strains were evaluated (E. faecalis type 2 and FA2-2
(CPS-C), type 5 [CPS-D]). Anti-LTA was chosen as control
because natural LTA-specific antibodies were present in the
diheteroglycan antiserum and because identical vaccination
protocols including complete Freunds adjuvant were used for
production of both antisera. Forty-eight hours after infection,
bacterial counts from the blood, kidneys and liver were
enumerated. At this time point, mice of both immunization
groups had cleared the bacteremia, but – depending on the E.
faecalis challenge strain - bacterial counts in the kidney and liver
were reduced 1.4 to 3.4 logs in mice immunized with
diheteroglycan-specific antibodies compared to mice that had
received rabbit anti-LTA (Fig. 6).
Discussion
Defining serotypes and corresponding structures of the cell
envelope that constitute the basis of serospecificity is a critical
step in vaccine development. Using formaldehyde-killed bacteria
for immunization, in 1992, Maekawa identified 21 serotypes of
E. faecalis by cross-agglutination and absorption studies [26].
More recently, Hufnagel defined a simplified serotyping system
based largely on carbohydrate antigens of E. faecalis [4].
Figure 3. Specificity of antibodies raised by vaccination with whole bacterial cells of E. faecalis. (A) Binding of rabbit IgG raised against
whole bacterial cells of E. faecalis type 2 to diheteroglycan and LTA purified from the same strain. The coating antigen and serum dilutions are
indicated in the legend. (B) Absorption of opsonic activity against E. faecalis type 2 (CPS-C) and type 5 (CPS-D) by cell envelope carbohydrate
antigens. Rabbit antiserum raised against whole bacterial cells of the respective target strain was used. For the inhibition opsonophagocytic killing
assay, rabbit antiserum was preincubated for 60 min with 10 mg/ml of either LTA or diheteroglycan purified from the homologous E. faecalis strain
and used at a final dilution of 1:800 in the assay. Bars are means and error bars the SEM four determinations.
doi:10.1371/journal.pone.0017839.g003
Figure 2. Structural characterization of diheterglycan by nuclear magnetic resonance (NMR) analysis. (A) The
1H NMR spectrum of
diheteroglycan isolated from E. faecalis type 2. The spectrum was recorded at 600 MHz and 27uC. The letters refer to the carbohydrate residues as
shown in chemical structure (Fig. 2C), and the numbers refer to the protons in the respective residues; LA, lactic acid. (B) Sections of the ROESY
spectrum of E. faecalis diheteroglycan. The interresidual NOE contacts are underlined. (C) Chemical structure of the repeating unit of E. faecalis
capsular diheteroglycan. * Acetic acid remain of the final gel-permeation chromatography step.
doi:10.1371/journal.pone.0017839.g002
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vaccination with purified polysaccharide or heat-killed, protein-
ase K-digested whole bacteria, and strains were typed according
to cross-reactivity measured by ELISA and the opsonophagocytic
killing assay. Using this methodology, 60% of a total of 29
clinical E. faecalis isolates could be assigned to one of four
serotypes, CPS-A to CPS-D [4]. However, serospecificity of
opsonic antibodies was not unequivocal between CPS-A and
CPS-B strains or between CPS-C and CPS-D strains [4].
McBride and Gilmore examined the diversity of capsule
expression in E. faecalis on a genetic basis in 106 strains of
diverse origin and found that approximately half of the strains
lacked genes of the cps locus that are essential for capsule
production [21].
Our group has demonstrated previously that the teichoic acid-
like cell envelope polysaccharide that is the target of opsonic
antibodies in CPS-A strains is structurally identical to LTA [3].
Using the highly purified LTA obtained from our previous study
we reassessed the cross-reactivity of LTA-specific antibodies. In a
previous publication by us, we demonstrated that opsonic
antibodies against CPS-A and CPS-B serotypes are not cross-
reative [4]. In our current study antibodies raised against purified
LTA reacted with both CPS-A strains (E. faecalis 12030) and CPS-
B strains (E. faecalis 12107, OG1RF, type 1). The discrepancy of
our current and previous study may be related to the different
antigen preparations used for production of rabbit antisera. For a
previous investigation we utilized a partially deacylated and
dealanylated LTA molecule that may have lost antigenic
properties during the purification process [3,4]. Our finding that
CPS-A and CPS-B only represent a single serotype is supported
by genetic characterization of the cps-locus: CPS-A and CPS-B
strains both contain only the first two cps-genes (cpsA and cpsB)b u t
lack remaining the genes of this locus (cpsC – cpsK) which are
essential for capsule production [4,15]. Also, LTA-specific
antibodies agglutinate CPS-A and CPS-B but not CPS-C and
CPS-D strains, indicating that LTA is surface exposed in the
former serotypes [15].
In contrast to acapsular CPS-A and CPS-B strains, our and
Thurlow’s data indicate that LTA of CPS-C and CPS-D strains is
not available on the bacterial surface to bind specific antibodies for
opsonization via the classical pathway, probably because a
polysaccharide capsule masks this antigen [14]. With evidence
suggesting the presence of an antiphagocytic capsule in E. faecalis,
we next purified cell envelope polysaccharides from the CPS-C
strain E. faecalis type 2 and identified a novel diheteroglycan.
The isolated diheteroglyan represented only a small propor-
tion of carbohydrates released by enzymatic digestion of
peptidoglycan. Most of the material obtained by this mode of
extraction was a rhamnopolysaccharide with similar composition
as described previously [8,9,10,11,12,22]. The diheterglycan
Figure 5. Relationship of diheteroglycan to the biosynthetic product of the cps locus. (A) Loss of opsonic activity after absorption of rabbit
antiserum raised against E. faecalis type 2 (CPS-C) diheteroglycan with whole bacteria. Before the assay the serum was absorbed with either E. faecalis
FA2-2 (CPS-C) wild type or its isogenic, acapsular cpsI mutant (E. faecalis HG101) for 60 min. Absorbed serum was used at a final dilution of 1:40 in the
assay. Bars represent the mean of four determinations and the error bar the SEM. (B) Native PAGE of purified diheteroglycan from E. faecalis type 2
(lane 1), cell wall lysates of E. faecalis FA2-2 wild type (CPS-C, lane 2) and the isogenic cpsI mutant (HG101, lane 3). Cell envelope carbohydrates were
released by digestion of peptidoglycan by lysozyme and mutanolysin and acrylamide gels were stained with Stains-All according to the method of
Hancock et al. [12].
doi:10.1371/journal.pone.0017839.g005
Figure 4. Opsonophagocytic killing of E. faecalis CPS-serotype C
and D strains by rabbit antiserum after immunization with
diheteroglycan purified from E. faecalis type 2 (CPS-C). Serum
dilutions were used as indicated in the legend. Bars represent the mean
of four determinations and the error bar the SEM.
doi:10.1371/journal.pone.0017839.g004
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lysaccharide and LTA during the chromatographic separation
process, making it challenging to isolate this carbohydrate in
high purity. Capsule extracts from two additional E. faecalis
strains (FA2-2 [CPS-C] and type 5 [CPS-D]) contained a
polysaccharide with an identical repeating unit of R6)- b-Galf-
(1R3)- b-D-Glcp-(1R.I nE. faecalis type 2 we recovered this
polysaccharide with and without O-acetylation in position C-5 of
Galf, while the polysaccharide isolated from E. faecalis type 5 and
FA2-2 lacked O-acetylation. Since O-acetyl substituents are pH
labile and hydrolyzed under mild basic conditions, the O-
deacetylated diheteroglycan may represent an artifact of the
conditions we have chosen for column chromatography.
Alternatively, we cannot exclude that the degree of O-acetylation
varies due to minor differences in culture conditions between the
batches used for purification. O-acetyl groups may influence the
biochemical properties of carbohydrates (e.g. solubility in water).
They also can be part of antigenic epitopes of bacterial
polysaccharides recognized by opsonic antibodies [27] but may
also mask them [28].
Pazur et al. described a diheteroglycan of very similar
composition in E. faecalis [5,6]. The proposed structure of Pazur’s
diheteroglycan is a backbone consisting of a trisaccharide
repeating unit of R4)-b-Glc-(1R6)-b-Glc-(1R4)-b-Gal-(1R sub-
stituted with lactosyl and cellobiosyl side chains attached by b-
(1R4) linkages to alternate glucose residues of the backbone [5].
Since this structure was determined before the availability of
NMR spectrometry for more definitive carbohydrate analysis, it is
tempting to speculate that this molecule is in fact identical with
the carbohydrate identified by us. The composition of our
diheteroglycan also bears resemblance to the capsular polysac-
charide described by Hancock and Gilmore [12,15] although
these authors never reported complete structural information for
their antigen. Their capsular polysaccharide is synthesized by the
Figure 6. Passive protection by rabbit antiserum in a mouse bacteremia model. Six to eight weeks old female Balb-C mice were passively
immunized by i.p. injection of 200 ml of heat-inactivated rabbit antiserum raised against diheterglycan (anti-DHG) from E. faecalis type 2 or LTA
purified from E. faecalis 12030 (anti-LTA) 24 and 12 h before and 4 h after infection. Fourty-eight h after i.v. injection of bacteria via the tail vein, mice
were sacrificed and bacterial counts quantified. Mice were infected with E. faecalis FA2-2 (3.0610
9 cfu per mouse), E. faecalis type 2 (2.0610
9) and E.
faecalis type 5 (2.5610
9) as indicated in the graph. Bars represent geometric means. Seven to eight mice per group were used. The lower limit of
detection was 10 CFU/ml. Groups of mice were compared using the T-test of log-transformed CFU counts.
doi:10.1371/journal.pone.0017839.g006
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position of the material isolated from strain FA2-2 (CPS-C) was
determined to be glucose, galactose, glycerol and phosphate at a
ratio of 4:1:1:2 [12]. Serum absorptions experiments, acrylamide
gel elecrophoresis and structural data presented here suggest that
both polysaccharide antigens – diheteroglycan and capsular
polysaccharide produced by the cps locus - are identical. Our
studies demonstrate that opsonic antibodies directed against
diheteroglycan bind to capsule-bearing CPS-C strains, but not to
its isogenic acapsular mutant. Also, both antigens co-migrate in
native PAGE and contain glucose and galactose, albeit at
different ratios. We can only speculate about the reason for this
discrepancy in monosaccharide composition, but impurities in the
capsular polysaccharide described by Hancock may explain the
compositional differences. As mentioned above, the diheterogly-
can partially co-elutes during the chromatography process with
LTA and only an additional purification step following ion
exchange chromatography yielded pure material in our study.
Hence, impurities of LTA could explain why Hancock and
Gilmore found more glucose, glycerol and phosphate in their
preparations of capsular polysaccharide. Of note, high-pH anion-
exchange chromatography–pulsed-amperometric detection em-
ployed for compositional analysis in Hancock’s study is not
suitable to detect LTA in mixtures of complex carbohydrates
[12,15].
To test if capsule-specific antibodies can protect against E.
faecalis infection, we passively immunized mice with either anti-
diheteroglycan or anti-LTA rabbit serum and challenged them
with E. faecalis CPS-C and CPS-D strains intravenously. Bacterial
counts were 1.4–3.4 logs lower in kidneys and livers of mice
immunized with anti-diheteroglycan for the three strains tested.
The variable protective efficacy against the tested E. faecalis strains
is somewhat surprising, but may be explained by differences of in
vivo expression or the degree of O-acetylation of diheteroglycan
between strains. In broader terms, this level of reduction of
bacterial load by passive protection is comparable if not superior
to vaccine efficacy achieved for various vaccine antigens evaluated
in Staphylococcus aureus [29,30,31,32]. It is difficult to predict, if this
level of vaccine efficacy in mice will translate into protection in the
human host. In contrast to other Gram-positive pathogens like
Streptococcus pneumoniae or group-B streptococci, which are virulent
pathogens in humans and mice, mice clear enterococcal
bacteremia or peritonitis spontaneously unless a very high
inoculum (.10
8–10
9 bacteria per mouse) is given. Hence, in our
animal model we may have overwhelmed adaptive immunity with
bacterial loads much higher than encountered during human
infection, a problem that also riddles vaccine research for other
nosocomial pathogens of low virulence (e.g. Staphylococcus epidermi-
dis, Candida spp.). Nevertheless, we expect that conjugation of the
diheteroglycan capsule to a protein carrier will enhance immuno-
genicity of the vaccine and elicit better protection in vivo. Active
and passive vaccination strategies with a diheteroglycan conjugate
vaccine could potentially be employed in patients that are at high
risk of invasive enterococcal infections such as patients hemato-
logic malignancies, neutropenia, or liver-transplant recipients
[33,34,35].
In summary, the results presented in this study provide
evidence that two carbohydrates of the cell envelope are targets
of opsonic antibodies in typeable strain of E. faecalis.A c t i v e
vaccination with LTA and diheteroglycan or a passive immuno-
therapy approach using recombinant human monoclonal anti-
bodies could therefore target non-encapsulated and capsule-
expressing strains and may provide protection against a majority
of E. faecalis strains.
Materials and Methods
Bacterial strains and culture
Bacterial strains and the respective serotype according to
Hufnagel et al. are specified in table 1. Unless otherwise indicated,
bacterial cells were grown from starter cultures in Columbia broth
(Becton Dickinson, Sparks, MD, USA) supplemented with 1%
glucose at 37uC until they reached an optical density at 600 nm of
0.6 to 0.8 and harvested by centrifugation.
Antisera
Rabbit antisera against whole bacterial cells of E. faecalis type 2
and type 5 have been described previously [4]. Anti-LTA rabbit
antiserum was prepared using LTA purified from E. faecalis 12030
by butanol extraction and hydrophobic interaction chromatogra-
phy [3]. Antiserum against diheteroglycan and LTA was raised by
s.c. immunization of one female New Zealand white rabbit for
each antigen with 100 mg of antigen suspended in complete
Freund’s adjuvant followed by the same dose in incomplete
Freund’s adjuvant seven days later and intravenous booster doses
of 10 mg every three days in the consecutive week. Antiserum was
obtained five weeks after the beginning of the immunization.
Preparation and characterization of capsular
polysaccharide
Diheteroglycan of E. faecalis was isolated by methods similar to
those described previously [3,22]. Briefly, E. faecalis strains type 2,
FA2-2 and type 5 were cultivated as described above and
harvested by centrifugation. The bacteria were washed in PBS
and cell walls were digested by addition of mutanolysin and
lysozyme (each at 100 mg/ml, Sigma Chemicals, St. Louis, MO,
USA in PBS supplemented with 5 mM MgCl2, 1 mM CaCl2 and
0.05% NaN3)a t3 7 uC for 18 h. Insoluble material was removed by
centrifugation, and the supernatant was treated with nucleases
(DNase I and RNase A, 100 mg/ml) at 37uC for 4 h followed by
addition of proteinase K (100 mg/ml, all Sigma Chemicals) at
56uC for 18 h. The supernatant was precipitated by the addition
of ethanol (80% final volume), collected by centrifugation, dialyzed
against deionized H2O, and lyophilized. For size exclusion
chromatography, the material was redissolved in 0.01 M ammo-
nium carbonate buffer (pH 8.0) and applied to a column
(1.6690 cm) of Sephacryl S-400 (GE Healthcare, Uppsala,
Sweden). Fractions eluting at around a Kav of 0.45 were
combined, dialyzed and lyophilized. The material was resus-
pended in 20 mM NaHCO3, pH 8.4 and applied to an anion-
exchange column (Sepharose Q FF, GE Healthcare). Bound
antigen was eluted from the column by a linear gradient of 0–1 M
NaCl and fractions were assayed for hexose content by the Dubois
assay and for phosphorus using the Lowry method [36,37].
Hexose-positive and phosphorus-negative fractions eluting at
450 mM NaCl were combined, dialyzed and lyophilized. As a
final purification step, gel-permeation chromatography was
performed on a 1.5675 cm Toyopearl HW-40 column (Tosoh
Corporation, Tokyo, Japan).
Preparation of LTA
LTA was prepared by butanol extraction and hydrophobic
interaction chromatography as described previously [3]. LTA
preparations were evaluated for purity by the Bradford assay,
SDS-PAGE and western blot analysis with the respective
antiserum to whole bacterial cells (see above). Structural identity
of LTA was confirmed by NMR spectroscopy as described
recently [3].
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Protein and phosphorus content of purified diheteroglycan as
quantified using standard assays [36,38]. The polysaccharide was
further characterized by SDS-PAGE in gradient gels (4/12% w/v,
Invitrogen), followed by staining for proteins with Coomassie blue
and with the PAS reaction for carbohydrates [39]. Compositional
analyses were performed as described previously [3,40,41].
Polyacrylamide gel electrophoresis
Cell wall carbohydrates were released from E. faecalis FA2-2 or
HG101 by treatment with mutanolysin, lysozyme and nuclease
and proteinase K treatment as described above. Next, 25%
ethanol was added and precipitated material was discarded. More
ethanol was added to a final concentration of 75% for the
precipitation of carbohydrates. Purified diheteroglycan and cell
wall extracts were analyzed by electrophoresis through 3%
polyacrylamide (33:1) in Tris-borate buffer (0.2 M Tris-base/
0.2 M boric acid/20 mM EDTA, pH 8.3), and detected using
Stains-All (3,39-dimethyl-9-methyl-4,5,4959-dibenzothiacarbocya-
nine) according to the method of Hancock et al. [12].
NMR spectroscopy
Samples were exchanged three times with 99.90%
2H2O,
lyophilized, and redissolved in 99.99%
2H2O. All one-dimensional
and two-dimensional spectra were recorded at 27uC with a Bruker
DRX Avance 600 MHz spectrometer as described previously [3].
Chemical shifts were reported relative to internal acetone (dH
2.225; dC 31.45).
ELISA studies
ELISA experiments were performed by standard methods as
described previously [3]. In brief, microtiter plates were coated
with the carbohydrate antigen specified in the respective
experiment (10 mg/ml in 0.04 M phosphate buffer, pH 7.0) and
incubated for 18 h at 4uC. Washing steps were performed with
PBS containing 0.05% Tween 20. Plates were blocked with 3%
skim milk in PBS-0.02% sodium azide at 37uC for 2 h. A goat
anti-rabbit IgG alkaline phosphatase conjugate (Sigma) diluted
1:1,000 was used as secondary antibody, and p-nitrophenyl
phosphate was used as a substrate (Sigma). After 60 min of
incubation at 37uC, the absorbance was measured at 405 nm.
Opsonophagocytic killing assay
An opsonophagocytic killing assay was used with modifications
as previously described [3,42]. In brief, E. faecalis strains were
grown to logarithmic phase (OD 600 nm 0.4) in TSB and diluted
in RPMI plus 15% heat-inactivated fetal calf serum. Baby rabbit
serum (Cedarlane Laboratories, Hornby, Ontario, Canada)
absorbed with the target bacterial strain served as a source of
complement. White blood cells (WBC) were isolated from healthy
volunteers by sedimentation with heparin-dextrane [42]. Rabbit
immune serum was heat-inactivated at 56uC for 30 min before use
and diluted to the concentration indicated for the individual
experiments. 2.5610
6 white blood cells, 2.5610
6 CFU of E.
faecalis, 0.00125–2.5% rabbit antiserum (as indicated in the
individual experiment), and 1.7% complement in a total volume
of 400 ml were incubated in tubes and rotated end over end at
37uC for 90 min. Negative controls included tubes from which
leukocytes, complement or serum were omitted. The opsonic
activity of the serum was calculated as follows: {1 - (CFU immune
serum at 90 min/CFU of control without WBC at 90 min)} x 100.
For studies on inhibition of opsonophagocytic killing, rabbit
antiserum was incubated at a concentration of 1:800 (final
concentration) with various concentrations of inhibitor for
60 min at 4uC. After incubation, the opsonophagocytic killing
assay was continued with the absorbed antiserum as described
above. Inhibition assays were performed at serum dilutions
yielding ,70 – 80% killing of the inoculum without the addition
of the inhibitor (for individual dilutions see text). The percentage
of inhibition of opsonophagocytic killing was compared to controls
without inhibitor.
Mouse bacteremia model
To test protective efficacy of rabbit immune serum, we
employed a modified mouse bacteremia model developed
previously in our laboratory [42,43,44]. Six- to eight-week old
female BALB-C mice (7–8 mice per group) were injected i.p. with
200 ml of heat-inactivated rabbit immune serum 48 h and 24 h
before and 4 h after bacterial challenge and infected intravenously
as indicated in the individual experiments. After 48 h, mice were
sacrificed, blood, kidneys and livers were harvested under sterile
conditions and bacterial counts enumerated by culture of serially
diluted samples. The lower limit of detection of the assay was
1610
1 CFU.
Ethics statement
All animal experiments were performed in compliance with the
German animal protection law (TierSchG). The mice were housed
and handled in accordance with good animal practice as defined
by FELASA and the national animal welfare body GV-SOLAS.
The animal welfare committees of the University of Freiburg
(Regierungspra ¨sidium Freiburg Az 35/9185.81/G-07/15) ap-
proved all animal experiments. The institutional review board of
the University of Freiburg approved the study protocol and written
informed consent was obtained from all study participants.
Statistcal analysis
Statistical significance for two-way comparisons was determined
by an unpaired t test. Analysis of variance (ANOVA) for
multigroup comparisons was used on log-transformed data, and
the Tukey’s multiple-comparison test was used for posthoc analysis
for pairwise comparisons. Statistical results were calculated using
the Prism 3 software package.
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1H and
13C NMR data of the capsular polysaccharide
from E. faecalis strain type 2. Spectra were recorded of a solution in
2H2O at 600 MHz and 27uC relative to internal acetone (dH
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underlined.
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Figure S5 ELISA of rabbit antiserum raised against purified
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